3 hedge funds and family offices disclose a GSK position in their latest SEC 13F filing — combined $79.6M in market value. Of those, 1 are classified as value investors.
| # | Investor | Fund | Shares | Value | % of Portfolio | Filed |
|---|---|---|---|---|---|---|
| 1 | Ray Dalio | Bridgewater Associates LP | 1,416,525 | $69.5M | 0.25% | 2025-12-31 |
| 2 | Mark Hillman | Hillman Capital Management Inc | 114,336 | $5.6M | 3.53% | 2025-12-31 |
| 3 | Tweedy Browne | Tweedy Browne Company LLC | 81,785 | $4.5M | 0.36% | 2026-03-31 |
As of the latest 13F window, 3 tracked superinvestors hold GSK. The largest disclosed position is Ray Dalio at $69.5M (0.3% of portfolio).
13F filings are due 45 days after each quarter end and capture long-equity positions held by U.S. institutional managers with $100M+ AUM. Use this page to see exactly who is buying GSK, how concentrated each position is, and the implied conviction level relative to the rest of each investor's book.
Key takeaways
